We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celgene's Otezla Gains Positive Recommendation from NICE
Read MoreHide Full Article
Celgene Corporation announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla. NICE has recommended Otezla for the treatment of adults with active psoriatic arthritis, who have had an inadequate response to or have been unable to tolerate disease modifying anti-rheumatic drugs (DMARDs). It does not require pre-screening for tuberculosis or regular laboratory monitoring.
Celgene’s share price has fallen 2.5% in the past one month, while the Zacks classified Medical-Biomedical and Genetics industry has witnessed a fall of 4.8%.
Otezla was assessed under the NICE Rapid Review process, after an initial negative guidance was issued by the NICE in Sep 2015. The drug alone or in combination with DMARDs is now recommended with DMARDs with a Patient Access Scheme for the treatment of adults with active psoriatic arthritis. It will be administered to patients suffering from peripheral arthritis with 3 or more tender joints and to unresponsive patients after adequate trials of at least 2 standard DMARDs, given either alone or in combination.
Patients in England and Wales can now access Otezla through the National Health Service, bringing availability of the drug in line with patients in Scotland, where it was recommended by the Scottish Medicines Consortium in Jun 2015.
The latest development is encouraging considering that psoriatic arthritis causes substantial strain on NHS resources. According to Celgene’s press release, more than 296,000 people in the UK are affected by this is complex chronic disease.
Earlier this week, Celgene announced that Japanese Ministry of Health, Labor and Welfare granted full marketing authorization to Otezla. It has been approved for the treatment of adults with plaque psoriasis, with an inadequate response to topical therapies, as well as adults with psoriatic arthritis.
Following the approval, Otezla has become the first oral treatment in 25 years to be cleared in Japan for the treatment of both psoriasis and psoriatic arthritis patients.
Zacks Rank & Key Picks
Celgene currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 83.7% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 11.8% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 9.2% and 3.4%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price gained 27.5% year to date.
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celgene's Otezla Gains Positive Recommendation from NICE
Celgene Corporation announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla. NICE has recommended Otezla for the treatment of adults with active psoriatic arthritis, who have had an inadequate response to or have been unable to tolerate disease modifying anti-rheumatic drugs (DMARDs). It does not require pre-screening for tuberculosis or regular laboratory monitoring.
Celgene’s share price has fallen 2.5% in the past one month, while the Zacks classified Medical-Biomedical and Genetics industry has witnessed a fall of 4.8%.
Otezla was assessed under the NICE Rapid Review process, after an initial negative guidance was issued by the NICE in Sep 2015. The drug alone or in combination with DMARDs is now recommended with DMARDs with a Patient Access Scheme for the treatment of adults with active psoriatic arthritis. It will be administered to patients suffering from peripheral arthritis with 3 or more tender joints and to unresponsive patients after adequate trials of at least 2 standard DMARDs, given either alone or in combination.
Patients in England and Wales can now access Otezla through the National Health Service, bringing availability of the drug in line with patients in Scotland, where it was recommended by the Scottish Medicines Consortium in Jun 2015.
The latest development is encouraging considering that psoriatic arthritis causes substantial strain on NHS resources. According to Celgene’s press release, more than 296,000 people in the UK are affected by this is complex chronic disease.
Earlier this week, Celgene announced that Japanese Ministry of Health, Labor and Welfare granted full marketing authorization to Otezla. It has been approved for the treatment of adults with plaque psoriasis, with an inadequate response to topical therapies, as well as adults with psoriatic arthritis.
Following the approval, Otezla has become the first oral treatment in 25 years to be cleared in Japan for the treatment of both psoriasis and psoriatic arthritis patients.
Zacks Rank & Key Picks
Celgene currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 83.7% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 11.8% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 9.2% and 3.4%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price gained 27.5% year to date.
CELGENE CORP Price
CELGENE CORP Price | CELGENE CORP Quote
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>